AI

InnerScope Hearing Technologies Announces Partnership with Atlazo Inc. to develop next-generation AI based hearable products

InnerScope Hearing Technologies, Inc. | November 12, 2021

InnerScope Hearing Technologies Inc. ("InnerScope"), the leader in direct-to-consumer (DTC) and over-the-counter (OTC) hearing solutions, announced today its partnership with Atlazo Inc. ("Atlazo") to develop next-generation hearing aids and hearable products, utilizing Atlazo's patented Artificial Intelligence (AI) hardware platform. Hearing products powered by Atlazo's proprietary ultra-low power System-on-Chip (SoC) will offer consumers unprecedented new features, including voice commands, continuous health monitoring, and seamless connectivity with other smart devices.

Mr. Adnan Shennib, Chief Technology Officer of InnerScope, stated: "Consumers will not only benefit from improved hearing in noisy environments but also from natural ways to interact with other wireless devices, including mobile phones, providing an enhanced, more convenient, user experience."

Atlazo's integrated digital hardware platform reduces cost and time-to-market for manufacturers of wearable devices. The SoC platforms include software algorithms designed specifically for wearable healthcare applications. The Atlazo and InnerScope collaboration targeting hearing applications are protected by over 12 issued and pending patents.

"We are pleased to join forces with InnerScope and its iHEAR team to develop new types of smart hearing products, leveraging iHEAR's extensive domain experience in hearing health," stated Karim Arabi, Founder and CEO of Atlazo. "Offering new types of intelligent hearing products with improved performance and affordability will be welcomed by tech-savvy consumers looking for alternatives to conventional hearing aids."

"With the recent FDA OTC regulations being released last month, including a landmark proposal intended to improve access to and reduce the cost of hearing aid technology for millions of Americans, and the anticipation of this OTC Law to be enacted soon, InnerScope is continuing to execute its plan to be the leader in the direct-to-consumer hearing device market.  The Atlazo partnership and our iHear research and development team give InnerScope the ability to develop new innovative types of proprietary artificial intelligence-powered hearing products that transcend today's hearing devices so all consumers, whether they have hearing loss or not, can benefit from using them."

Matthew Moore, President and CEO of InnerScope Hearing Technologies

About InnerScope Hearing Technologies, Inc

InnerScope Hearing Technologies Inc. is a leading manufacturer and distributor of FDA-registered hearing aids and Personal Sound Amplifier Products (PSAPs) dedicated to addressing the global demand for affordable hearing solutions. InnerScope's hearing products and business models breakthrough persistent barriers that prevent access to effective hearing solutions. With the recent Acquisition of iHear Medical Inc., a cloud-based hearing solution provider with access to over 40 patents, and the completion of HearingAssist Acquisition, an established leader in the direct-to-consumer hearing aid market with over 400,000 customers, InnerScope is well-positioned to expand its distribution partnership network and its leadership in the direct-to-consumer hearing solutions market with advanced hearing products offered at a fraction of the cost of conventional hearing aids sold in hearing aid centers.  

About Atlazo

Atlazo is the leader in intelligent semiconductor solutions for healthcare and wearable, targeting the rapidly growing hearing and wearable health device markets. Founded in 2016 and headquartered in San Diego, CA, the company is dedicated to addressing the global demand for more reliable health tracking and audio by bringing together cutting-edge innovations in energy-efficient AI and flexible bio-sensing interface in a single System-on-Chip (SoC) solution. Atlzao's innovative SoC products offer manufacturers a platform for rapid development of wearable healthcare products, dramatically reducing costs and time-to-market. 

Spotlight

Many healthcare delivery systems continue to operate with a fee-forservice mindset. Practices simply treat patients when they come into the office, providing uncoordinated, on-demand services in response to an immediate clinical need and then billing patients health plans.

Spotlight

Many healthcare delivery systems continue to operate with a fee-forservice mindset. Practices simply treat patients when they come into the office, providing uncoordinated, on-demand services in response to an immediate clinical need and then billing patients health plans.

Related News

FUTURE OF HEALTHCARE

BioIntelliSense Joins Polaris Dawn Mission to Advance Understanding of Human Health in Space

BIOINTELLISENSE | November 15, 2022

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Medical and scientific research on human health in space promotes the advancement of translational technologies by adapting known technology for space applications, and by using space-based insights to improve healthcare at home. “BioIntelliSense has proudly gained industry recognition for its innovative and comprehensive portfolio of continuous multi-parameter monitoring solutions for application in the acute care environment, at home settings and now, in the next frontier of space, As a lifelong space exploration enthusiast, it is a tremendous honor to be working with TRISH on health research that can benefit astronauts and crews during commercial space flight and for the BioButton devices to be part of the upcoming Polaris Dawn mission.” -James Mault, MD, founder and CEO of BioIntelliSense The BioButton multi-parameter device is designed to be worn on the upper left chest and will passively capture trending physiologic and movement data from the Polaris Dawn crew during its milestone mission. The future of healthcare is here. Today, the BioIntelliSense Data-as-a-Service (DaaS) platform and clinical intelligence solution is commercially available and rapidly adopted by acute and post-acute providers in the U.S. along with select international markets. TRISH is proud to partner with innovative healthcare technology leaders like BioIntelliSense as we further our understanding of human health in space, Our EXPAND (Enhancing eXploration and ANalog Definition) commercial spaceflight health research platform provides unique opportunities to rapidly test technologies in orbit, as well as collect new datapoints on the health impact of spaceflight for a wider, more diverse population,said James Hury, TRISH Chief Innovation Officer and Deputy Director. BioIntelliSense (Booth #5025) and TRISH (Space Health Pavilion #2636) will be showcasing the BioButton wearable device and clinical intelligence solution at the premier HLTH 2022 conference November 13 – 16 in Las Vegas, NV. ABOUT BIOINTELLISENSE BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home. ABOUT TRANSLATIONAL RESEARCH INSTITUTE for SPACE HEALTH (TRISH) Led by Baylor College of Medicine’s Center for Space Medicine, TRISH is a consortium that includes partners Caltech and MIT. NASA recently awarded the Institute a six-year extension to further its work by delivering disruptive solutions to mitigate biomedical risks for human exploration while advancing terrestrial health technologies.

Read More

HEALTH TECHNOLOGY

Eleos Health and The Echo Group Announce Strategic Partnership to Advance the use of Augmented Intelligence in Behavioral Health

Eleos Health and Echo Group | September 16, 2022

Eleos Health, the leader in CareOps Automation for behavioral health, and The Echo Group, the only provider of visual electronic health record technology, announced that Eleos Health's augmented intelligence will be directly embedded into the EchoVantage web-based clinical, billing, and administrative EHR application to serve the needs of behavioral healthcare clinicians. Eleos Health and EchoVantage will act in synergy to reduce administrative burdens on clinicians. Medical professionals face an increasing number of administrative tasks, spending an average of 20% of their total working hours on administration. In general, notes for each session take about 15 minutes to complete, with the average full-time clinician doing so for 40 sessions per week. Eleos will turn behavioral health conversations into documentation and session intelligence, plugging directly into EchoVantage's visual health record (VHR). The VHR provides clinicians with a client's case across a timeline, with visual indicators providing an understandable and actionable graphical format. Clinicians using Eleos reduce time spent on documentation by over 30%. This increase in efficient and accurate documentation also equips supervisors with unprecedented visibility into staff activity, caseloads and performance to make it easier for providers to meet organizational standards for documentation, while empowering providers to improve training with structured, objective feedback on their sessions. "Eleos Health is excited to add The Echo Group to our growing base of strategic partners who are dedicated to advancing the standard of care in behavioral health. By enhancing the EchoVantage EHR with our augmented intelligence capabilities, we will give clinicians the ability to spend less time on administrative tasks and more time impacting the lives of those managing behavioral health conditions," Alon Joffe, CEO and Co-Founder, Eleos Health EchoVantage ensures that all aspects of the clinical chart are fully integrated and organized, along with the timeline, in relation to each other. This lends true clinical understanding to precipitating events and treatment activities. "The expansion of our national offering to include Eleos Health as an embedded platform for all of our customers is a huge benefit for clinicians and their patients," said Allan Normandin, Chief Executive Officer, The Echo Group. "The Echo Group is focused on finding ways to empower our customers to be more clinically effective and financially strong. Working with Eleos Health is another step in achieving that goal by reducing the barrier of administrative tasks in the continuum of care." This partnership puts overburdened clinicians back into the office working with clients instead of spending their time typing notes into their EHR. Beyond simplifying documentation, , this partnership will enable clinicians to quickly understand the themes in their meetings, such as suicidal thoughts or cognitive-behavioral therapy techniques, and pursue the best evidence-based practices. Eleos Health's proprietary voice-based Natural Language Understanding (NLU) technology accurately identifies evidence-based techniques, as well as interprets the meaning of behavioral health conversations, giving clinicians objective feedback they can use with patients to identify recurring themes, issues and needs. Eleos Health will be available to all of The Echo Group's clients as an add-on, with GRAND Mental Health, in Northeastern and North Central Oklahoma, being the first center to leverage the power of both systems to help give its care providers more time for patients. The Echo Group's partners are located throughout the U.S. and range in size, from small community behavioral health agencies to comprehensive enterprise-wide organizations. "The ability to reduce administrative burdens for clinicians while also increasing visibility around the quality of care is invaluable in giving our staff the freedom and tools they need to focus on our mission of improving quality of life for consumers," said Josh Cantwell, COO, GRAND Mental Health. "The Eleos Health and Echo Group partnership will meaningfully ability to support clinicians and serve our communities." About Eleos Health Founded in 2020, Eleos Health turns behavioral health conversations into documentation and intelligence that drives better care. Using proprietary, voice-based Natural Language Understanding (NLU) technology built by clinical experts to accurately interpret, analyze and document behavioral health conversations, Eleos reduces the operational burden on providers while unlocking objective insights into evidence-based care and the therapeutic alliance. Leadership teams can scale supervision and training while gaining unprecedented visibility into staff activity, caseloads and performance as well as population health. Eleos is the only technology of its kind that embeds seamlessly into electronic health records (EHRs), telehealth tools and existing provider workflows. With Eleos CareOps Automation, behavioral health providers are setting a new standard for care. About The Echo Group The Echo Group, privately held since 1980, revolutionized electronic health records in the behavioral health industry with EchoVantage, the only EHR featuring a visual continuum of care timeline. EchoVantage is a core, integrated EHR platform with a complete suite of tools designed to conform to your workflow, meet compliance requirements, and increase productivity, enabling you to spend more time putting your clients. The Echo Group is located in Conway, New Hampshire, with an additional office in California. Echo has more than 80 employees dedicated to making the best behavioral health technology in the industry.

Read More

HEALTH TECHNOLOGY

GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics

GE Healthcare | October 17, 2022

At the European Association of Nuclear Medicine Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform. This cutting-edge system features a brand-new category of digital BGO detector material with a small crystal size that delivers more than two times the sensitivity of prior digital scannersii, enabling faster total scan timesiii and impressive small lesion detectabilityiv. It is designed to improve operational efficiency, enhance the patient experience, and increase diagnostic power, ideally helping to enable improved patient outcomes. Additionally, the system’s theranosticsv capabilities and ability to image short life tracers, as well as dynamic protocolsvi, help empower clinicians with greater clinical information across more oncology, cardiology, and neurology procedure types than ever before. “Sensitivity and image quality are everything in PET/CT,” explains John Kennedy, Ph.D., Chief Physicist, Nuclear Medicine Department, Rambam Health Care Campus, and Lecturer at Technion – Israel Institute of Technologyvii. “Omni Legend delivers on both – meeting all our image quality criteria for oncology and providing impressive sensitivity to image high count tracers for cardiac and neuro imaging, which helps better inform patient diagnoses and monitoring. Also, we have been able to increase patient throughput by more than a third thanks to the system’s fast total scan times – even achieving 35 patient scans in a 9.5-hour shift – and reduce dose by 40% versus the previous equipment that was installed. This not only enables better patient access and experience but also allows us to increase overall hospital efficiencyviii.” As the pace of change in healthcare continues to increase, health plan leaders cite managing costs and driving operational efficiency as the top two challenges they face todayix. This is consistent with comments by global Molecular Imaging departments, which note operational efficiency as a top barrier to growing PET/CT procedure volumesx. Omni Legend is GE Healthcare’s response to these growing challenges, helping healthcare systems overcome today’s barriers with a collection of intuitive workflow solutions enhanced by artificial intelligence (AI), including its new Precision DLi solution for deep learning image processing in PET/CT as well as its AI-based Auto Positioning Camera. “Having access to high-quality images to determine patient care is foundational to administering quality healthcare,” adds Prof. Zohar Keidar, Director of Nuclear Medicine & the PET/CT Department at Rambam and an Associate Clinical Professor at the Technion Faculty of Medicinevii. “With this in mind, a department like ours – which has a very heavy workload – requires a system that enables flexibility for emergency cases, in addition to our already packed schedules. Omni Legend provides that flexibility. Within a few short weeks/months, we were able to increase our number of scans by 150 percent – going from 30 to 45 patient scans per day. We used to have a long wait list; but today, if something is urgent, we can quickly scan a patient while keeping our other scheduled appointmentsviii. And the system’s clinical protocols afford us additional flexibility, allowing us to stage patients on any scanner, regardless of the system the patients was previously scanned on – affording us new opportunities in fleet management.” More than a new processing technique, Precision DLi is engineered using Deep Learning with a sophisticated deep neural network trained on thousands of images created with different reconstruction methods. It was designed to provide the image quality performance benefits most associated with hardware-based Time-of-Flight, such as better contrast-to-noise ratio, contrast recovery, and quantitative accuracy. The capabilities of Omni Legend are further elevated by the inclusion of Q.Clear (BSREM), GE Healthcare’s pioneering PET image reconstruction technology, and MotionFree, the company’s proven, deviceless respiratory motion correction technology. Q.Clear helps to ensure reliable quantification, while MotionFree operates seamlessly in the background to correct respiratory motion artifacts for all patient types. Furthermore, the new system’s operational efficiency solutions help improve the PET/CT imaging experience for both the technologist and the patient with convenient features that provide A fast data quality assurance process that saves time with streamlined calibration; Simplified protocol selection on the gantry touchscreen and a new user interface to enable an easy PET/CT process from start to finish; and Enhanced patient positioning capabilities as a result of AI-based Auto Positioning that automatically centers the patient for a completely hands-free positioning experience. This streamlined patient setup frees up technologists to focus on making patients feel more comfortable. Omni Legend also features LED ambient lighting to encourage a calming mood as well as a graphic pattern for the patient to view in the system to help in both alleviating stress and reducing movement for nervous patients. “We built our scalable Omni platform from the ground up to meet the needs of our customers and their patients today and in the future. With the patient in mind, we leaned on our longstanding technological leadership and strong clinical collaborations to enhance the scan experience with entirely new components designed to help improve clinical outcomes. The result is an all-digital detector, a cutting-edge deep learning solution, and workflow enhancements to help enable more personalized care.” Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE Healthcare Omni Legend was designed with theranostics in mind, enabling clinicians to reach new levels of sensitivity and detectability for incredibly clear images. Already, the system boasts the highest sensitivity per cm in the marketxi and images Gallium 68 for diagnosis, staging, or restaging. Future-ready capabilities include a multi-directional, upgradable platform that can potentially expand in each of the core dimensions of PET/CT imaging, including axial field-of-view, digital detector technology, software, CT capabilities, and imaging of new tracers. About GE Healthcare GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Read More